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Muscle and bone 
weakening
Dysregulation of the 
immune system
Elevated kidney stone 
risk
Fluid 
Redistribution to 
upper body
Elevated radiation 
may increase 
cancer risk
Plasma volume 
decreases, anemia
Otoliths in inner 
ear respond 
differently, eyes 
become main 
way to sense 
motion
Spaceflight Effects on Human Physiology
Vision Issues
•One of largest tissues in the human body, 
although largely in fluid state.
•Consists primarily of white blood cells 
(WBCs) located in lymph nodes and the 
peripheral blood. 
•Responsible for protection against viral 
and bacterial infection, latent viral 
reactivation, tumor surveillance, wound 
healing, etc.
•Dysregulation can result in increased 
infection rate, malignancy, autoimmunity, 
allergy, etc.
The Immune System
Humoral immunity - Antibody mediated, 
effector cell B cells/plasmacytes.   
Antibodies bind specific antigens, signals 
other cells to engulf, kill and remove that 
substance from the body
Cell mediated immunity - Cell 
mediated.  Effector cell cytotoxic T 
lymphocytes  which destroy viral infected 
cells, transplant cells, some tumor cells   
Innate Immunity - primary defense, 
immediate (constitutively present), non-
specific, does not result in memory
Adaptive Immunity - Acquired; 
secondary defense, delayed (components 
not constitutively present), antigen-
specific, results in memory
The Immune System

The Cytokine Network
Innate/
Inflammatory
Adaptive/
regulatory
Humoral
Chemokines
Growth Factors
Th1/Th2


Skylab Data - 1973
ISS Sample Types:
• Blood
• Saliva (Liquid)
• Saliva (Dry)
• Urine
• Health Survey
Early
~2 weeks
Mid
2-4 mos
Late
R-1-2 days
L-180 L-45 R+0 R+30
Preflight In-flight Postflight
ISS Sample Schedule:
JSC 
Immunology 
Laboratory
Mercer 
University
Microgen 
Laboratories
JSC Microbiology 
Laboratory
• Latent herpesvirus 
reactivation (saliva/urine)
• Leukocyte subsets
• Intracellular cytokine profiles (4hr 
culture)
• T cell function (24h culture)
• Mitogen-stimulated cytokine 
profiles (48h culture)
• Virus specific T cell number
• Virus specific T cell function
• Plasma cytokine balance
• Leukocyte cytokine RNA
• Stress hormone levels
• Circadian rhythm alignment
PHYSIOLOGICAL 
STRESS
Immune System 
Changes
Adverse clinical 
outcomes
(Latent Viral Reactivation)(Status and Function)


Comprehensive Peripheral Phenotype
“Diseases are often accompanied by changes in the numbers or function of ‘fine’ lymphocyte subsets, even if changes in the bu lk lymphocyte 
populations are not evident”  
-De Rosa, Roederer, et. al. Nature Medicine 7(2), 245-255, 2001.
• Remove cells from body
• Stimulate cells with mitogens during 
culture, mimics an in-vivo immune 
response
T cell function
Cytokine Secretion
Proliferation
Kinetics of T Cell Activation
T Cell Function vs. Disease
T Cell Function:   
Early Blastogenesis
(24hr Culture)
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T cell function (early blastogenesis) data, expression of either 
CD69, or CD69/CD25 dual following 24hr culture in the presence 
of (A) staphylococcal enterotoxin A and B;  or (B) antibodies to 
CD3 and CD28.  Data are presented as mean ± standard error.  
Significance was evaluated by comparing all other data points to 
L-180 baseline data. Significant differences (p≤ 0.05) are 
indicated (*).  Sample size for all data is 19 ISS astronaut 
subjects
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Secreted Cytokine Profiles:  Detection by Cytometric Bead Array
• Stimulate cells in the presence of 
any mitogen (anti-3/28, PMA-I, LPS)
• Incubate for 48 hours
• Isolate and purify supernatants
• Freeze for batch analysis
• Analyze for cytokine concentrations 
by CBA
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Secreted Cytokine Profiles:  Mean ISS Data (n=17)
48hr Culture – anti CD3/CD28 Stimulation
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Mean secreted cytokine levels following mitogenic stimulation. Data are 
expressed mean concentration in pg/ml ± SEM.  * indicates statistically significant 
difference p≤0.05.  Significance was evaluated by comparing all other data points 
to L-180 baseline data. Significant differences (p≤ 0.05) are indicated (*).  Sample 
size for all data is 19 ISS astronaut subjects
Secreted Cytokine Profiles:  Mean ISS Data (n=23)
48hr Culture – PMA/I Stimulation
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Latent Herpesvirus Reactivation in ISS Crewmembers
Circadian Misalignment in ISS Crewmembers
Circadian rhythm of 
Salivary Cortisol in 
27 healthy adults
Pierson and Mehta 2013
Plasma Cytokine Analysis
Early
~2 weeks
Mid
2-4 mos
Late
R-1-2 days
FD15
FD30
FD60
FD120
FD180
SMO-018
SMO-016
Mean Baseline Cytokine Concentrations
Cytokine
IL-1a 0.3 ± 0.1 0.4 ± 0.3 0.9 ± 0.5 0.3 ± 0.1 2.4 ± 1.9 0.6 ± 0.2 0.3 ± 0.1 0.3 ± 0.1 0.3 ± 0.1
IL-1b 0.4 ± 0.1 0.7 ± 0.3 1.5 ± 1.0 0.8 ± 0.3 0.9 ± 0.5 1.3 ± 0.9 1.1 ± 0.8 0.5 ± 0.2 0.8 ± 0.3
TNFa 1.4 ± 0.1 1.4 ± 0.1 3.2 ± 1.0 2.0* ± 0.3 2.1 ± 0.4 2.2 ± 0.5 2.0 ± 0.4 1.3 ± 0.1 1.7 ± 0.2
IL-6 0.3 ± 0.1 0.3 ± 0.1 0.5 ± 0.2 0.3 ± 0.1 0.4 ± 0.1 0.3 ± 0.1 0.3 ± 0.1 1.1* ± 0.2 0.3 ± 0.1
IL-8 2.0 ± 0.3 2.1 ± 0.3 8.1* ± 2.1 7.9* ± 2.3 7.7* ± 1.7 7.3* ± 2.1 6.9* ± 2.3 2.1 ± 0.3 2.3 ± 0.4
IL-1ra 383 ± 40 370 ± 35 567* ± 65 563* ± 80 638* ± 101 728* ± 129 661* ± 85 682* ± 118 568 ± 146
IFNg 0.8 ± 0.2 0.8 ± 0.2 0.6 ± 0.1 0.7 ± 0.2 0.8 ± 0.2 0.9 ± 0.2 0.7 ± 0.3 0.5* ± 0.1 0.7 ± 0.2
IL-2 2.2 ± 0.6 1.8* ± 0.5 1.7* ± 0.5 2.6 ± 0.8 2.4 ± 0.7 2.5 ± 0.7 2.4 ± 0.8 2.4 ± 0.7 2.7 ± 0.9
IL-17 1.3 ± 0.3 1.1 ± 0.3 0.9 ± 0.2 1.0 ± 0.2 1.1 ± 0.3 1.1 ± 0.2 0.9 ± 0.3 0.9* ± 0.2 0.9 ± 0.2
IL-4 0.3 ± 0.1 0.5 ± 0.3 3.2 ± 1.7 0.3 ± 0.2 1.4 ± 0.7 2.1 ± 1.5 1.6 ± 1.2 0.4 ± 0.2 0.2 ± 0.1
IL-5 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0
IL-10 0.2 ± 0.0 0.2 ± 0.1 0.4 ± 0.2 0.2 ± 0.0 0.2 ± 0.0 0.4 ± 0.2 0.2 ± 0.0 0.3 ± 0.1 0.4 ± 0.1
G-CSF 7.2 ± 1.9 7.0 ± 1.7 7.0 ± 1.8 4.5 ± 0.8 7.6 ± 2.0 14.7 ± 7.8 9.8 ± 3.2 10.3* ± 2.8 5.9 ± 1.4
GM-CSF 0.6 ± 0.3 0.3 ± 0.1 3.4 ± 1.9 1.9* ± 0.8 2.7 ± 1.3 2.8 ± 1.9 2.7 ± 1.9 0.7 ± 0.4 0.7 ± 0.4
FGFb 13.7 ± 5.4 15.4 ± 5.7 11.8 ± 3.3 21.9 ± 5.7 18.5 ± 4.9 12.1 ± 3.7 10.8 ± 2.7 11.7 ± 3.8 12.3 ± 4.3
Tpo 140 ± 16 146 ± 18 184* ± 18 189* ± 30 191* ± 22 196* ± 28 221* ± 24 141 ± 17 133 ± 16
VEGF 5.8 ± 0.9 6.2 ± 1.3 10.9* ± 1.9 15.8* ± 4.9 11.3* ± 1.7 12.5* ± 3.5 11.7* ± 1.9 5.1 ± 1.0 5.5 ± 0.9
CCL2/MCP-1 72.4 ± 6.8 78.5 ± 7.7 71.7 ± 5.4 66.0 ± 5.8 77.0 ± 7.0 84.0 ± 7.0 87.0 ± 7.7 124* ± 18.1 90* ± 7.5
CCL3/MIP-1a 20.3 ± 5.0 16.6 ± 5.0 25.9 ± 8.1 15.0 ± 4.4 19.1 ± 6.6 22.7 ± 7.4 21.7 ± 8.6 19.4 ± 6.3 18.1 ± 5.5
CCL4/MIP-1b 16.2 ± 2.2 16.7 ± 2.7 22.3* ± 2.9 20.2* ± 2.5 22.2* ± 2.8 24.3 ± 5.1 21.6* ± 3.3 17.3 ± 2.3 19.3 ± 4.0
CCL5/RANTES 3613 ± 263 3292 ± 246 3618 ± 202 3746 ± 195 3575 ± 185 3818 ± 217 4030 ± 202 3410 ± 266 3623 ± 219
CXCL5/ENA-78 231 ± 58 367 ± 219 2065* ± 371 1858* ± 310 2015* ± 360 1749* ± 309 1860* ± 388 190 ± 48 202 ± 55
L-180 L-45
Spaceflight
FD180 R+0 R+30FD120FD30 FD60FD15
Table 2:  Mean plasma cytokine levels for ISS astronauts before, during, and following spaceflight. Data are expressed as 
mean concentration pg/ml ± SEM.  Bold indicates statistically significant difference p≤0.05; n=28.
Plasma Cytokine Analysis
• A definitive tabulation in the literature is lacking, although various 
NASA activities have created incidence numbers (Clinical Finding 
Forms, etc.)
• Inability to confirm diagnoses
• Restricted to electronic/remote examination
• Treatment options limited
• Data privacy restricted
• Missions vary in workload, stress
• Surgeons may record data differently
• Crew may be reluctant to report medical events
Clinical Incidence onboard ISS?
• Spacecraft a perfect ‘petri dish’ for germs (confined space, recycled air, touching common 
surfaces with less opportunity to wash)
• Aerosolized germs (microdroplets) do not settle out due to gravity
• Immune system inhibited, microbes more virulent
Total Events/
events person year
Allergic Reaction 1 0.06
Anaphylaxis 0 ---
Upper Respiratory Infection (combination of rhinitis, nasal 
stuffiness and sneezing)
5 0.301
Eye Infection 0 ---
Herpes Zoster 5 0.301
Otitis Media/Externa (ear pain, or ear stuffiness+congestion) 17 1.022
Pharyngitis (sore throat) 1 0.06
Sepsis 0 ---
Sinus Infection 0 ---
Skin Infection (including scalp pruritis, pus forming wounds on 
wrist, finger)
5 0.301
Skin Rash/Hypersensitivity (including skin conditions such as 
tinea versicolor, dermatitis, rosacea) 
23 1.383
Urinary Tract Infection 1 0.06
Malignancies* 0 ---
Autoimmunity* 0 ---
Infections, Other*# 11 0.666
Total: 69 4.18
Medical Conditions
Table II:  Incidence data, ISS Program, Expeditions 1 to 28/29; 37 ISS crewmembers; 
total flight duration 6072 days/16.63 person years.  
Source JSC Epidemiology Group: A. Babiak-Vazquez, Sara Mason and Jessica Garcia. 
*Indicates additional conditions or symptoms categorized, beyond the original 13 IMM conditions.  
#Additional infectious processes not characterized within other categories such as lymphadenitis, 
lymphadenopathy, mild fever and intestinal problems with such symptoms as diarrhea, excessive 
intestinal gas and bloating.
ISS Incidence Tabulation Data tabulated from 37 long-duration ISS crewmembers 
(Exp. 1-28/29; totals 16.63 person flight years)
Case Study ISS Astronaut
• Unusually proficient medical record
• Typical busy pre-mission training schedule
• Launch on Soyuz;  docking to ISS + 2 days
• 191 day mission onboard ISS
• 3 Shuttle dockings, 2 Progress dockings, 1 
ATV docking
• 5 EVA activities (12 Shuttle EVA)
• Typically busy mission schedule
• Landing on Soyuz, GCTC 1 week
Case Study ISS Astronaut
-Allergic symptoms in a non-allergic
subject
-Subject developed an Atopic
Dermatitis on mission day 17
-Rash was bothersome, at times
severe
-A variety of treatments employed
-At times the medications of choice
were exhausted
-Rash never resolved for the duration of the mission, although it was 
successfully managed to a tolerable level
-Rash spikes generally correlated well with operational stressors
-Research findings confirm immune dysregulation persisted for the duration 
of the mission
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                     MEDICATIONS KEY
• Rashes were observed to occur in the 
following locations:  scalp, face, neck, 
chest, back, trunk, abdomen, arms and 
hands. 
• The appearance of the rashes generally 
consists of bumps/nodules and/or small 
brown scaly patches, with or without 
petechiae, redness/hyperemia and 
itching.   
General Rash Characterization
Plasma Cytokine Profile
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Circadian Rhythm of Salivary Cortisol
Working Hypothesis:  Spaceflight Summary Effects on Immunity
↓ Skin DTH during flight
↓ T cell Function (general and virus specific)
↓ Adaptive immunity cytokine profile
↑Persistent herpesvirus reactivation
No known effect on humoral immunity
(MIR-18 vaccination study)
↓ NK cell function
↑Persistent hypersensitivity/pro-allergy
↑ Persistent systemic low-grade inflammation 
(Possible localized inflammation)
INNATE
ADAPTIVE
Th1Th2 Cytokine Bias shift
Conclusions
Immune System dysregulation persists during 6-month orbital spaceflight
Appears to be a pan-suppression of adaptive function, some sensitization 
of innate immunity
Latent herpesviruses, including VZV, persistently reactivate for the duration 
of a 6-month ISS mission.
Circadian misalignment occurs, difficult to regain a ‘normal’ circadian 
rhythm.  (Sleep meds most commonly prescribed Rx)
Conclusions
• Case study:  Mission events correlated well with observed 
symptomology
• Spaceflight is a granular experience consisting of chronic stress 
interspersed with periodic acute stressors
• Immune dysregulation during flight appears to be polar, with some 
adaptive processes depressed (T cell function, HV shedding); whereas 
some innate and other processes are elevated (inflammation, 
hypersensitivity reactions)
• Exploration immune countermeasures must be considered carefully
Immune Countermeasures for Exploration Missions?
Considerations
Have we completely characterized in-flight immune dysregulation?
Is there a clinical risk from the observed pattern of dysregulation?
Is the phenomenon likely to be exacerbated beyond Earth orbit?
What specific cellular dysregulation should be targeted for correction?
Countermeasures must be carefully targeted
Can immune countermeasures exacerbate elevated incidence 
hypersensitivity reactions?
What is the interdisciplinary/multi-system impact of an immune 
countermeasure?
Upcoming Immune Investigations onboard ISS
Functional Immune  (NASA)
Immuno-2/Neyroimmunitet (ESA/RSA)
Moroze (RSA)
Exploration Atmosphere (NASA)
Categories Immunology Countermeasures
Tier 1
Multidiscipline, benign
Tier 2
Nutritional supplementation
Tier 3
Pharmacological intervention
Tier 0
Already in place
Pre-flight quarantine/Health Stabilization Program
The primary purpose of the Flight Crew Health Stabilization Program (HSP) is to mitigate 
the risk of occurrence of infectious disease among astronaut flight crews in the 
immediate preflight period. 
Infectious diseases are contracted through direct person-to-person contact, and through 
contact with infectious material in the environment. 
The HSP establishes several controls to minimize crew exposure to infectious agents. 
The HSP provides a quarantine environment for the crew that minimizes contact with 
potentially infectious material. 
The HSP also limits the number of individuals who come in close contact with the crew. 
The infection-carrying potential of these primary contacts is minimized by educating 
them in ways to avoid infections and avoiding contact with the crew if they are or may 
be sick. 
Primary contacts are also strongly encouraged to maintain updated vaccinations. 
JSC 22538 Revision D 
Tier 0
Already in place
Tier 0
Already in place
Vehicle Design Controls
• HEPA air filters
• In-line water filters
• Contamination resistant surfaces
• Water biocides
• Water pasteurization systems
• Minimize condensation
• Contain trash and human waste
C. Mark Ott, Ph.D., NASA Microbiologist 
Pre-Flight Screen of Crewmembers
MedB 2.1 (L-90; L-30) “The examination will include collection of blood 
and urine from crewmembers for analyses to enhance the physician’s 
medical evaluation of crew health prior to flight”
• CBC/Differential
• CRP
• Mouse IgE Allergen Panel
MedB 2.4  (L-90, L-30)  “…to determine transfer or acquisition of 
Methicillin-Resistant Staphylococcus aureus (MRSA)”
• Nasal Screen for Methicillin Resistant Staphylococcus 
aureus (MRSA) 
MedB 2.2 (L-21/18 months)  “To detect and eradicate H. Pylori from 
crewmembers preflight to mitigate risk”
• Serological H. Pylori IgG and IgA antibody test results; 
Urea Breath Test results, if indicated 
Tier 0
Already in place
Tier 0
Already in place
Preflight Microbiological Monitoring
• Crewmembers
• Food
• Potable water
• Vehicle surfaces
• Vehicle air
• Cargo
• Biosafety review of payloads
C. Mark Ott, Ph.D., NASA Microbiologist 
Tier 0
Already in place
Microbiological Monitoring Onboard ISS
AirSurfaces Water
Quantified in-flight and returned to JSC for identification
55C. Mark Ott, Ph.D., NASA Microbiologist 
Immune Countermeasures
•Environmental control
•ISS ‘Seat Swapping’
•Stress relieving techniques
•Exercise
•Sleep schedules
•Family communication
•Radiation shielding
•Propulsion/faster transit
•Yoga 
Tier 1
Multidiscipline, benign
Tier 2
Nutritional supplementation
•Supplemental nucleotides: Uridine/uridine (immune function)
•AHCC: active hexose-correlated compound (Th2 shift; innate 
immunity)
•Pegylated-IL-2 (NK cell #/function)
•Antioxidants (radiation effects, oxidative stress)
N-acetyl cysteine, ascorbic acid
a-lipoic acid
L-selenomethionine
Coenzyme Q10
vitamin E succinate
D-selenomethionine
Immune Countermeasures
Tier 2
Nutritional supplementation
•Omega 3 fatty acids (anti-inflammatory properties)
•Probiotics
•Wellimmune™
•BAM-FX (Zero Grav Sol. Inc.) 
•Plant Extracts
Immune Countermeasures
Langston Immune Countermeasures Study
Probiotics/Extracts of Probiotics
• Probiotics modulate innate and adaptive immunity (Aureli 2011)
• Mechanisms and actions of probiotics not fully understood (Oelschlaeger 2010)
• Supplementation with probiotics has positive benefits on the response to vaccination 
for influenza (Olivares 2007), polio (De Vrese 2005) and cholera (Paineau 2008)
• Positive effects may be via the release of cytokines after ingestion (Maassen 2008)
Plant Extracts
• 47% of pharmaceuticals trace to natural origins (Newman 2007)
• Plant derived medicines also modulate immune responses.
• Saikosaponin from Bupleurum falcatum – increased IL-2 production (Yamaguchi 1985)
• Silybum marianum (milk thistle) immunostimulatory (Wilasrusmee 2002)
Biochemistry
• Transcriptomic data from probiotics and plant compounds
• Combinations of lead compounds with and without addition of dietary vitamins and 
minerals
Tier 2
Nutritional supplementation
Sinus congestion and allergy symptom treatments included OTC antihistamines, 
decongestants, and adrenergics as well as prescription antihistamines and mast 
cell stabilizers.
Sleep medications among the most prescribed on-orbit
Medication efficacy may be altered during 
Spaceflight (no data).
Medication Use onboard ISS
Wotring, V.E., Medication Use by U.S. Crewmembers on the International Space Station (Abstract #1023.1).  
Experimental Biology 2015, March 28-April 1, 2015, Boston, Mass.
Fluid shifts may effect absorption 
and distribution of medications.
There are some animal studies that 
indicate drug metabolism, ie liver 
enzymes, may be altered.
Tier 3
Pharmacological intervention
Tier 3
Pharmacological intervention
•Anti-Cortisol  (Ketoconozole)
•Non-Steroidal anti-Inflammatory 
•Beta blockers (Propranolol)
•Cytokine Antagonists/Blockers (IL-1, TNF, IL-4, IL-9, IL-13)
•Recombinant Cytokine Therapy
Immune Countermeasures?
•Antibiotics
•Antiviral
•Corticosteroids
Treatment of Medical Events
•Supplemental nucleotides: Uridine/uridine (immune function)
•AHCC: active hexose-correlated compound (Th2 shift; innate immunity)
•Pegylated-IL-2 (NK cell #/function)
•Antioxidants (radiation effects, oxidative stress)
N-acetyl cysteine, ascorbic acid
a-lipoic acid
L-selenomethionine
Coenzyme Q10
vitamin E succinate
D-selenomethionine
•Omega 3 fatty acids (anti-inflammatory properties)
•Probiotics
•Wellimmune™
•BAM-FX (Zero Grav Sol. Inc.)
Summary Chart - Immunology Countermeasures
•Ketoconozole
•Antibiotics
•Antiviral
•Anti-inflammatory
•Beta blockers
•Cytokine therapy
•Environmental control
•Stress relieving techniques
•Exercise
•Sleep schedules
•Family communication
•Radiation shielding
•Propulsion/faster transit 
•Antiviral (VZV) vaccination
Tier 1
Multidiscipline, benign
Tier 2
Nutritional supplementation
Tier 3
Pharmacological intervention
Other options
•Pre-flight quarantine
•Microbial screening of vehicle/payloads/foods
•Med ops screening
Tier 0
Already in place

brian.crucian-1@nasa.gov

